Avance Biosciences, Inc., a leading biological testing company supporting drug development and manufacturing, announced today that its Houston facility was inspected by the U.S. Food and Drug Administration on October 01 through October 04, 2018. This inspection focused on the firm’s quality management system, operation procedures, and data integrity, as well as various analyses performed [...]
Digital PCR (dPCR) provides precise and absolute quantification of nucleic acids without a standard curve and without dependence on amplification efficiency. It is ultrasensitive; therefore, appropriate for testing allelic variants and targets of low abundance that are below the sensitivity limit of QPCR. It is also very precise, and is a better tool than QPCR [...]
In the week of March 18, 2012, Avance Biosciences entered a Master Service Agreement (MSA) with a global leader in custom biologics manufacturing. Based on this agreement, Avance Biosciences will provide its GMP level Cell Bank Characterization services, including DNA Sequencing, qPCR, Southern blot and other molecular biological methods, to characterize the Master Cell Bank (MCB), Working Cell Bank (WCB), and End of Production Cells (EOPC) submitted by the clients.
To Our Esteemed Customers and Friends: We would like to bring to your attention that Avance Biosciences Inc. has been formed by a group of experienced genomic scientists, quality professionals, biotechnology services experts, and enthusiastic investors. The founders of the company, combined, have more than 100 years of experience in the genomics and biotechnology services [...]